| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Received on March 16, 2005
Accepted on July 18, 2005
Endocrinology and Metabolism |
1 Research Department, B.R.A.H.M.S AG, Biotechnology Centre Hennigsdorf/Berlin, Germany
* To whom correspondence should be addressed. E-mail: n.morgenthaler{at}brahms.de.
Background: Adrenomedullin (ADM) is a potent vasodilatory peptide, and circulating concentrations have been described for several disease states, including dysfunction of the cardiovascular system and sepsis. Reliable quantification has been hampered by the short half-life, the existence of a binding protein, and physical properties. Here we report the technical evaluation of an assay for midregional pro-ADM (MR-proADM) that does not have these problems.
Methods: MR-proADM was measured in a sandwich immunoluminometric assay using 2 polyclonal antibodies to amino acids 45-92 of proADM. The reference interval was defined in EDTA plasma of 264 healthy individuals (117 male, 147 female), and increased MR-proADM concentrations were found in 95 patients with sepsis and 54 patients with cardiovascular disease.
Results: The assay has an analytical detection limit of 0.08 nmol/L, and the interassay CV was <20% for values >.12 nmol/L. The assay was linear on dilution with undisturbed recovery of the analyte. EDTA-, heparin-, and citrate-plasma samples were stable (<20% loss of analyte) for at least 3 days at room temperature, 14 days at 4 °C, and 1 year at -20 °C. MR-proADM values followed a gaussian distribution in healthy individuals with a mean (SD) of 0.33 (0.07) nmol/L (range, 0.10-0.64 nmol/L), without significant difference between males or females. The correlation coefficient for MR-proADM vs age was 0.50 (P <0.001). MR-proADM was significantly (P <0.001) increased in patients with cardiovascular disease [median (range), 0.56 (0.08-3.9) nmol/L] and patients with sepsis [3.7 (0.72-25.4) nmol/L].
Conclusions: MR-proADM is stable in plasma of healthy individuals and patients. MR-proADM measurements may be useful for evaluating patients with sepsis, systemic inflammation, or heart failure.
The following articles in journals at HighWire Press have cited this article:
|
|
 |
|
  C. Maier, M. Clodi, S. Neuhold, M. Resl, M. Elhenicky, R. Prager, D. Moertl, G. Strunk, A. Luger, J. Struck, et al. Endothelial Markers May Link Kidney Function to Cardiovascular Events in Type 2 Diabetes Diabetes Care, October 1, 2009; 32(10): 1890 - 1895. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. T. Huang, D. C. Angus, J. A. Kellum, N. A. Pugh, L. A. Weissfeld, J. Struck, R. L. Delude, M. R. Rosengart, and D. M. Yealy Midregional Proadrenomedullin as a Prognostic Tool in Community-Acquired Pneumonia Chest, September 1, 2009; 136(3): 823 - 831. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Smith, C. Newton-Cheh, B. Hedblad, J. Struck, N. G. Morgenthaler, A. Bergmann, T. J. Wang, and O. Melander Distribution and Correlates of Midregional Proadrenomedullin in the General Population Clin. Chem., August 1, 2009; 55(8): 1593 - 1595. [Full Text] [PDF]
|
|
|
|
 |
|
 O. Melander, C. Newton-Cheh, P. Almgren, B. Hedblad, G. Berglund, G. Engstrom, M. Persson, J. G. Smith, M. Magnusson, A. Christensson, et al. Novel and Conventional Biomarkers for Prediction of Incident Cardiovascular Events in the Community JAMA, July 1, 2009; 302(1): 49 - 57. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Adlbrecht, M. Hulsmann, G. Strunk, R. Berger, D. Mortl, J. Struck, N. G. Morgenthaler, A. Bergmann, J. Jakowitsch, G. Maurer, et al. Prognostic value of plasma midregional pro-adrenomedullin and C-terminal-pro-endothelin-1 in chronic heart failure outpatients Eur J Heart Fail, April 1, 2009; 11(4): 361 - 366. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Vila, M. Resl, D. Stelzeneder, J. Struck, C. Maier, M. Riedl, M. Hulsmann, R. Pacher, A. Luger, and M. Clodi Plasma NT-proBNP increases in response to LPS administration in healthy men J Appl Physiol, December 1, 2008; 105(6): 1741 - 1745. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Piccin, C. Murphy, E. Eakins, W. Murphy, J. Kunde, C. McMahon, and O. Smith Plasma Adrenomedullin Levels Are Elevated in Pediatric Patients with Severe Sickle Cell Anemia Blood (ASH Annual Meeting Abstracts), November 16, 2008; 112(11): 4795 - 4795. [Abstract] [Full Text]
|
|
|
|
|
|
D. Stolz, M. Christ-Crain, N. G. Morgenthaler, D. Miedinger, J. Leuppi, C. Muller, R. Bingisser, J. Struck, B. Muller, and M. Tamm Plasma Pro-Adrenomedullin But Not Plasma Pro-Endothelin Predicts Survival in Exacerbations of COPD Chest, August 1, 2008; 134(2): 263 - 272. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Szinnai, N. G. Morgenthaler, K. Berneis, J. Struck, B. Muller, U. Keller, and M. Christ-Crain Changes in Plasma Copeptin, the C-Terminal Portion of Arginine Vasopressin during Water Deprivation and Excess in Healthy Subjects J. Clin. Endocrinol. Metab., October 1, 2007; 92(10): 3973 - 3978. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Christ-Crain and B. Muller Biomarkers in respiratory tract infections: diagnostic guides to antibiotic prescription, prognostic markers and mediators Eur. Respir. J., September 1, 2007; 30(3): 556 - 573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Yoshihara, A. Ernst, N. G. Morgenthaler, T. Horio, S. Nakamura, H. Nakahama, H. Nakata, A. Bergmann, K. Kangawa, and Y. Kawano Midregional proadrenomedullin reflects cardiac dysfunction in haemodialysis patients with cardiovascular disease Nephrol. Dial. Transplant., August 1, 2007; 22(8): 2263 - 2268. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. C. Lim, N. G. Morgenthaler, T. Subramaniam, Y. S. Wu, S. K. Goh, and C. F. Sum The Relationship Between Adrenomedullin, Metabolic Factors, and Vascular Function in Individuals With Type 2 Diabetes Diabetes Care, June 1, 2007; 30(6): 1513 - 1519. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Q. Khan, R. J. O'Brien, J. Struck, P. Quinn, N. Morgenthaler, I. Squire, J. Davies, A. Bergmann, and L. L. Ng Prognostic Value of Midregional Pro-Adrenomedullin in Patients With Acute Myocardial Infarction: The LAMP (Leicester Acute Myocardial Infarction Peptide) Study J. Am. Coll. Cardiol., April 10, 2007; 49(14): 1525 - 1532. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Zudaire, S. Portal-Nunez, and F. Cuttitta The central role of adrenomedullin in host defense J. Leukoc. Biol., August 1, 2006; 80(2): 237 - 244. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Papassotiriou, N. G. Morgenthaler, J. Struck, C. Alonso, and A. Bergmann Immunoluminometric Assay for Measurement of the C-Terminal Endothelin-1 Precursor Fragment in Human Plasma Clin. Chem., June 1, 2006; 52(6): 1144 - 1151. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
